Clinical proteomics: Insights from IGF-I

Publication date: February 2018 Source:Clinica Chimica Acta, Volume 477 Author(s): Jakob Albrethsen, Hanne Frederiksen, Trine Holm Johannsen, Anna-Maria Andersson, Anders Juul Clinical proteomics aims to deliver cost-effective multiplexing of potentially hundreds of diagnostic proteins, including distinct protein isoforms. The analytical strategy known as targeted proteomics is particularly promising because it is compatible with robust mass spectrometry (MS)-platforms already implemented in many clinical laboratories for routine quantitation of small molecules (i.e. uHPLC coupled to triple-quadrupole MS). Progress in targeted proteomics of circulating insulin-like growth factor 1 (IGF-I) have provided valuable insights about tryptic peptides, transitions, internal standards and calibrants. The present challenge is to examine if targeted proteomics of IGF-I can truly measure up to the routine performance that must be expected from a clinical testing platform.

Source: Clinica Chimica Acta - December 23, 2017 Category: Laboratory Medicine Source Type: research